Esri Brings Powerful Mapping Technology to Everyone with New Storytelling Tool
Capturing and sharing life's experiences today often requires multiple platforms and tools, which can result in disjointed storytelling. To serve creators' needs to control their dynamic, interactive narratives in one place, Esri, the global leader in location intelligence, today released StoryMaps, a powerful, personal storytelling tool. The product extends Esri's creative capabilities to anyone who wants to tell their story and share it.
Using Esri's mapping technology, this new software brings the geographic approach to any content that creators are passionate about. From documenting their ancestral journey to capturing aspects of daily life or planning a first big post-pandemic trip, StoryMaps helps capture life's moments in a way worthy of those experiences.
"At Esri, we understand that sharing stories is a part of life, that everyone is a storyteller," said Jack Dangermond, Esri founder and president. "Every moment and memory we treasure is connected to a specific location, which is why we're making it easier to transport people anywhere in the world through richer storytelling."
Esri allows authors to control their narratives with built-in privacy to protect data and automatic content ownership and create them in versatile ways that reflect the experiences themselves. People can creatively combine text with multimedia like images, videos, audio, and links to easily share their personal experiences, hobbies, family history, ancestry, portfolios, travels, and more.
The National Geographic Society (NGS)—which for more than 130 years has been illuminating and protecting the world through science, exploration, education, and storytelling—is partnering with Esri to bring StoryMaps to its members.
"The National Geographic Society has a long legacy of storytelling, and it remains fundamental to our mission work today as we further our understanding of our planet and each other," said Jill Tiefenthaler, National Geographic Society chief executive officer. "Our partnership with Esri enriches this legacy, empowering our members to share their unique stories and experiences through this innovative geospatial tool."
Esri designed StoryMaps to enable everyone with varying digital skills to create custom content without requiring cartography or web design experience. StoryMaps allows authors to
- Build a story in one place. Make versatile stories of any length using your assets (text, photos, videos, audio, etc.) or leverage Unsplash for ready-to-use images.
- Publish and share your story with any audience. Make a private journal, create a shareable unlisted link for family and friends, or publish on all popular social media platforms. Authors can also embed stories on websites and blogs.
- Add custom interactive maps. Bring readers along your journey by adding a map with graphics and pop-ups or create a thematic map to visualize trends.
- Incorporate engaging features. Display content in different ways using flexible components including a timeline, image gallery, swipe, and quotes. All content can be organized into collections that act like folders.
- Customize the look. Choose from built-in themes or customize a design with a different font, color, and layout options.
- Keep it current. Update and publish stories easily with new features and capabilities every two weeks. Future features will include geo-ready data from wearables to show off your latest outdoor activities.
A free basic plan is available with essential storytelling capabilities to ensure all storytellers have access at any time. When new users sign up, they have free access to Premium features with enhanced storytelling capabilities for the first 30 days. After, they can decide to purchase a monthly or annual Premium subscription to StoryMaps at $10 or $100, respectively, or downgrade to the free, basic storytelling option.
To explore StoryMaps, read stories, and get started, visit storymaps.com.
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com.
Copyright © 2022 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, StoryMaps, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005532/en/
Contact information
Jo Ann Pruchniewski
Public Relations, Esri
Mobile: 301-693-2643
Email:
jpruchniewski@esri.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorriXR Therapeutics, InhaTarget Therapeutics, and Merxin Ltd Announce Strategic Collaboration for the Development of Inhaled Lung Cancer Treatment2.12.2025 15:30:00 EET | Press release
CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development and clinical validation of innovative treatments of pulmonary diseases by inhalation, and Merxin Ltd, a designer and supplier of inhaler devices, have entered a strategic collaboration to develop a pioneering inhaled genetic therapy targeting lung cancer. The partnership draws upon CorriXR’s proprietary CRISPR-based gene editing platform targeting NRF2, InhaTarget’s proprietary formulation platform and strong experience in pulmonary drug development, and Merxin Ltd’s advanced inhalation device technology. Through their combined expertise, they aim to create a patient-friendly inhaled therapy that delivers targeted treatment directly to lung tumors, maximizing efficacy, minimizing systemic side effects, and offering new hope for patients facing one of the world’s deadliest cancers. Innovativ
AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer2.12.2025 15:00:00 EET | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial (NCT05720130) evaluating its lead investigational candidate, ADVC001, in metastatic prostate cancer. The news follows the encouraging Phase 1b dose escalation results presented at the European Society for Medical Oncology (ESMO) 2025 congress that showed a favorable safety profile and compelling anti-tumor activity for ADVC001 in patients with mCRPC (see press release). ADVC001 is a first-in-class 212Pb-PSMA RLT in clinical development, with early data indicating a differentiated and competitive profile both within and beyond its class. Development is advancing rapidly; the Phase 1b therapeutic cohorts were enrolled within ten months, and the commencement of Phase 2 expansion sustains this strong program momentum. The TheraPb Phase 2 expansion will evaluate ADVC001 at two therapeutic dose levels – 160 MB
Luma AI Opens for International Business With Former WPP Executive Jason Day Leading New London Office2.12.2025 15:00:00 EET | Press release
Luma AI, the frontier artificial intelligence company building multimodal AGI intelligence and known for its flagship product Dream Machine, today announced a major step in its global expansion with the opening of its first international office in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202217704/en/ LUMA AI OPENS FOR INTERNATIONAL BUSINESS WITH FORMER WPP EXECUTIVE JASON DAY LEADING NEW LONDON OFFICE As creative economies decentralize and new production hubs emerge across EMEA, Luma AI is positioning its capabilities where creative work is increasingly being produced - not just consumed. To build intelligence that truly serves global creators, Luma AI will work alongside them in their markets, cultures, and workflows. London is the first step in that strategy, as it has the unique position as a global center of advertising, brands, and entertainment. “With this Series C raise and the upcoming build-out
Aurigene Oncology Limited Announces Encouraging Initial Data From 1 st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies2.12.2025 15:00:00 EET | Press release
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology,today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL). “We are very encouraged by the early results of the first two cohorts from our Phase 1 study of AUR112,” said Dr. Murali Ramachandra, CEO. “AUR112 has shown a promising initial clinical profile, achieving an overall response rate of 63.6% in the efficacy-evaluable population and 58.3% in the intent-to-treat group. These strong early data, combined with its distinct preclinical and safety characteristics, reinforce our belief that AUR112 has the potential to become
Eventbrite Enters into Definitive Agreement to Be Acquired by Bending Spoons for Roughly $500 Million to Accelerate Eventbrite’s Next Phase of Growth2.12.2025 14:30:00 EET | Press release
Eventbrite, Inc. (NYSE: EB), the leading global marketplace for shared experiences, announced today that it has entered into a definitive agreement to be acquired by Bending Spoons, in an all-cash transaction valued at approximately $500 million. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals and approval by Eventbrite’s stockholders. “For two decades, Eventbrite has stood at the forefront of the experience economy, helping tens of millions to create, discover, and attend unforgettable events,” said Luca Ferrari, Bending Spoons CEO and Co-Founder. “Joining forces with Bending Spoons will accelerate innovation and strengthen Eventbrite’s tools and resources to bring even more people together through shared live experiences for many years to come. As longstanding fans, we’ve identified a few opportunities that we’re excited about exploring with the Eventbrite team after closing the transaction. These include building a dedicated m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom